Biomarker Cyto3D® Live-Dead Assay Kit (Cat. No: BM01) The study explores the application of tumor organoid technology in borderline ovarian tumors (BOT), a category of tumors with limited treatment options and resistance to conventional chemotherapy. Researchers established patient-derived organoids (PDOs) to model BOT and evaluate potential therapeutic compounds, particularly Bractoppin, a BRCA1 carboxy-terminal domain (BRCT) […]
Culture apical-out organoids with xeno-free VitroGel® system
Hydrogel: VitroGel® ORGANOID 3 (Cat. No: VHM04-3) Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with limited treatment options and poor patient survival rates. A major challenge in treating PDAC is the tumor’s ability to create a protective barrier of mucins, which shields cancer cells from immune attacks and reduces the effectiveness of […]
BiomarkerCyto3D® Live-Dead Assay Kit (Cat. No: BM01) Cancer research has long been challenged by the complexity of tumor-immune interactions. Traditional 2D cell cultures and animal models often fail to capture the intricate tumor microenvironment (TME), limiting their relevance to human biology. Patient-derived precision-cut tumor slices (PCTS) offer a promising solution by preserving the tumor’s architecture […]
VitroGel® Hydrogel for In Vivo / Tissue Engineering Revolutionizing Cartilage Repair: Combining the VitroGel® System with a Bendable-Tip Arthroscopic Device for Controlled Hydrogel Extrusion
VitroGel® RGD played a key role in preserving tumor architecture for effective drug testing in lymphoma research. Hydrogel:VitroGel® RGD (Cat. No: TWG003) VitroGel® played a The fight against cancer, particularly B-cell lymphomas, is challenged by the complexity of tumor microenvironments and the need for personalized treatment strategies. Traditional models such as cell lines and xenografts […]
VitroGel® significantly enhanced the delivery of dexamethasone to the inner ear, providing controlled release and improved protection against cisplatin-induced hearing loss. Hydrogel: VitroGel® RGD (Cat. No: TWG003) VitroGel® played a crucial role in the study by enhancing the local delivery of dexamethasone (Dexa) to the inner ear. It facilitated a controlled and prolonged release of […]
VitroGel® revolutionizes colorectal cancer research by creating a xeno-free platform for patient-derived organoids, enabling groundbreaking insights into tumor-immune interactions and immunotherapy responses. Hydrogel:VitroGel® MSC (Cat. No: VHM03) Other VitroGel® option:VitroGel® ORGANOID-3 (Cat. No: VHM04-3) VitroGel® played a crucial role in establishing a patient-derived immunity-organoid interaction platform for colorectal cancer (CRC) research. By providing a xeno-free […]
VitroGel® ORGANOID empowered breakthrough single-cell pharmacotranscriptomic profiling by enabling robust, patient-specific cancer organoid models for drug discovery and resistance analysis. Hydrogel:VitroGel® ORGANOID-4 (Cat. No: VHM04-4) In this study, Dini et al. present a high-throughput pharmacotranscriptomic pipeline utilizing live-cell barcoding and single-cell RNA sequencing (scRNA-Seq) to analyze drug response mechanisms and resistance pathways in high-grade serous […]
VitroGel® ORGANOID-4 deepened ovarian cancer research by allowing 3D spheroid formation and transcriptomic analysis, identifying key signaling STAT1 and GREM1 activation pathways. Institutions:University of Oulu; Institute for Molecular Medicine Finland; University of Helsinki; Tampere University Hospital and Faculty of Medicine and Health Technology; Okayama University Graduate School of Medicine; Karolinska Institutet. Team:Emilia Piki, Alice Dini, […]
